126 related articles for article (PubMed ID: 38603866)
21. Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer.
Huang CJ; Teng HW; Chien CC; Lin JK; Yang SH
PLoS One; 2014; 8(6):e65117. PubMed ID: 23755178
[TBL] [Abstract][Full Text] [Related]
22. The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients.
Jácome AA; Vreeland TJ; Johnson B; Kawaguchi Y; Wei SH; Nancy You Y; Vilar E; Vauthey JN; Eng C
Br J Cancer; 2021 Feb; 124(4):797-804. PubMed ID: 33208919
[TBL] [Abstract][Full Text] [Related]
23. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
Frankel TL; Vakiani E; Nathan H; DeMatteo RP; Kingham TP; Allen PJ; Jarnagin WR; Kemeny NE; Solit DB; D'Angelica MI
Cancer; 2017 Feb; 123(4):568-575. PubMed ID: 27737491
[TBL] [Abstract][Full Text] [Related]
24. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
[TBL] [Abstract][Full Text] [Related]
25. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
26. Effect of KRAS and BRAF mutations in metastatic colorectal cancer patients: A systematic review and meta-analysis based on tumor sidedness and KRAS subtypes.
Saravani K; Salarzaei M; Parooie F
Hum Antibodies; 2021; 29(4):275-284. PubMed ID: 34334388
[TBL] [Abstract][Full Text] [Related]
27. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
[TBL] [Abstract][Full Text] [Related]
28. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
[TBL] [Abstract][Full Text] [Related]
29. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status.
Kamphues C; Kadowaki S; Amini N; van den Berg I; Wang J; Andreatos N; Sakamoto Y; Ogura T; Kakuta M; Pikouli A; Geka D; Daitoku N; Theochari M; Buettner S; Akiyama T; Antoniou E; Pikoulis E; Theodoropoulos G; Imai K; Ijzermans JNM; Margonis GA; Akagi K; Kreis ME
J Surg Oncol; 2021 Mar; 123(4):1005-1014. PubMed ID: 33368279
[TBL] [Abstract][Full Text] [Related]
30. Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions.
Margonis GA; Boerner T; Bachet JB; Buettner S; Moretto R; Andreatos N; Sartore-Bianchi A; Wang J; Kamphues C; Gagniere J; Lonardi S; Løes IM; Wagner D; Spallanzani A; Sasaki K; Burkhart R; Pietrantonio F; Pikoulis E; Pawlik TM; Truant S; Orlandi A; Pikouli A; Pella N; Beyer K; Poultsides G; Seeliger H; Aucejo FN; Kornprat P; Kaczirek K; Lønning PE; Kreis ME; Wolfgang CL; Weiss MJ; Cremolini C; Benoist S; D'Angelica M
Ann Surg; 2023 Sep; 278(3):e540-e548. PubMed ID: 36453261
[TBL] [Abstract][Full Text] [Related]
31. Critical appraisal of surgical margins according to KRAS status in liver resection for colorectal liver metastases: Should surgical strategy be influenced by tumor biology?
Rhaiem R; Duramé A; Primavesi F; Dorcaratto D; Syn N; Rodríguez ÁH; Dupré A; Piardi T; Fernández GB; Villaverde AP; Rodríguez Sanjuán JC; Santiago RF; Fernández-Moreno MC; Ferret G; Ben SL; Suárez Muñoz MÁ; Perez-Alonso AJ; Koh YX; Jones R; Martín-Pérez E; Kianmanesh R; Di Martino M
Surgery; 2024 Jul; 176(1):124-133. PubMed ID: 38519408
[TBL] [Abstract][Full Text] [Related]
32. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
[TBL] [Abstract][Full Text] [Related]
33. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.
Shoji H; Yamada Y; Taniguchi H; Nagashima K; Okita N; Takashima A; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Cancer Sci; 2014 Aug; 105(8):1002-7. PubMed ID: 24863535
[TBL] [Abstract][Full Text] [Related]
34. Mutation Status of
Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
[TBL] [Abstract][Full Text] [Related]
35. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
[TBL] [Abstract][Full Text] [Related]
36. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
Goldstein J; Tran B; Ensor J; Gibbs P; Wong HL; Wong SF; Vilar E; Tie J; Broaddus R; Kopetz S; Desai J; Overman MJ
Ann Oncol; 2014 May; 25(5):1032-8. PubMed ID: 24585723
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of the combination of microsatellite instability and
Yang Y; Wang D; Jin L; Wu G; Bai Z; Wang J; Yao H; Zhang Z
Cancer Manag Res; 2018; 10():3911-3929. PubMed ID: 30310312
[TBL] [Abstract][Full Text] [Related]
38. Effect of RAS and BRAF mutations on peritoneal metastasis risk and cytoreductive surgery/hyperthermic intraperitoneal chemotherapy efficacy in colorectal cancer: A systematic review and meta-analysis.
Gao Z; Qi X; Wang R; Wen Z; Qi H; Ju M; Liu X; Wang J; Zhou H; Zhu Z; Liu X; Li K
Eur J Surg Oncol; 2024 Jun; 50(9):108474. PubMed ID: 38870874
[TBL] [Abstract][Full Text] [Related]
39. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
Christensen TD; Palshof JA; Larsen FO; Poulsen TS; Høgdall E; Pfeiffer P; Jensen BV; Yilmaz MK; Nielsen D
Acta Oncol; 2018 Aug; 57(8):1057-1062. PubMed ID: 29380640
[TBL] [Abstract][Full Text] [Related]
40. [Surgical treatment of metastases and its impact on prognosis in patients with metastatic colorectal carcinoma].
Sevčíková K; Ušáková V; Bartošová Z; Sabol M; Ondrušová M; Ondruš D; Spánik S
Klin Onkol; 2014; 27(1):38-44. PubMed ID: 24635436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
